The global biopharmaceutical market is projected to grow from $396.8 billion in 2023 to $425.6 billion in 2024, while oncology and antibody therapeutics keep pulling the biggest shares forward. This post gathers the numbers behind growth, approvals, funding, manufacturing capacity, and even biosimilar uptake and shortages to show what is accelerating and what still holds progress back.
Key Takeaways
- 2023 global biopharmaceutical market size was $396.8 billion
- 2024 global biopharmaceutical market size is projected to reach $425.6 billion
- 2018–2023 global biopharmaceutical market CAGR was 6.7%
- The FDA approved 55 new molecular entities (NMEs) in 2023
- The FDA approved 48 NMEs in 2022
- The FDA approved 53 NMEs in 2021
- Global pharmaceutical R&D expenditure in 2023 was $226.7 billion
- Global pharmaceutical R&D expenditure in 2022 was $205.4 billion
- In 2023, industry R&D in Europe was €80.7 billion
- In 2023, the US had 8,614 biologic manufacturing facilities (including plasma and other)
- In 2022, FDA listed 8,100 biologic manufacturing facilities
- In 2021, FDA listed 7,600 biologic manufacturing facilities
- In 2023, FDA approved 35 biosimilars
- In 2022, FDA approved 17 biosimilars
- As of 2023, FDA had approved 37 biosimilars to filgrastim and pegfilgrastim
The biopharmaceutical market is growing fast, with 2024 revenue projected to reach $425.6 billion globally.
Market size & growth
12023 global biopharmaceutical market size was $396.8 billion[1]
Verified
22024 global biopharmaceutical market size is projected to reach $425.6 billion[1]
Verified
32018–2023 global biopharmaceutical market CAGR was 6.7%[1]
Directional
4Global oncology biopharmaceuticals market size in 2023 was $249.3 billion[2]
Verified
5Global oncology biopharmaceuticals market is projected to reach $285.7 billion in 2024[2]
Verified
6Global antibody therapeutics market in 2023 was $115.4 billion[3]
Single source
7Global antibody therapeutics market is projected to reach $124.4 billion in 2024[3]
Single source
8Global recombinant protein market size in 2023 was $21.5 billion[4]
Directional
9Global recombinant protein market is projected to reach $23.2 billion in 2024[4]
Single source
10Global vaccines market size is projected to reach $87.9 billion in 2024[5]
Verified
11In 2023, global vaccine market size was $75.0 billion[5]
Directional
12Global cell therapy market size is projected to reach $10.1 billion in 2024[6]
Verified
13Global gene therapy market size is projected to reach $8.5 billion in 2024[7]
Directional
14Biopharmaceuticals account for 28% of all new drugs approved by FDA between 2010–2020[8]
Directional
152022 global biotech industry revenues were $2.5 trillion[9]
Verified
16In 2023, the global biotech industry market size was $2.9 trillion[10]
Verified
17Biopharmaceuticals represented $368.5 billion of global drug sales in 2023[11]
Verified
18Biopharmaceuticals represented $372.2 billion of global drug sales in 2024 (estimate)[11]
Verified
19The US accounted for 46% of global biopharmaceutical sales in 2023[12]
Verified
20Europe accounted for 26% of global biopharmaceutical sales in 2023[12]
Verified
21China accounted for 6% of global biopharmaceutical sales in 2023[12]
Single source
22Japan accounted for 4% of global biopharmaceutical sales in 2023[12]
Verified
23Emerging markets accounted for 18% of global biopharmaceutical sales in 2023[12]
Verified
24The FDA approved 55 new molecular entities (NMEs) in 2023, of which 53% were novel biologics/biosimilars[13]
Single source
25The EMA’s centralized procedure resulted in 99 new marketing authorisations in 2023[14]
Single source
26In 2023, the EMA authorized 67 medicines for human use via the centralized procedure for major therapeutic areas[14]
Verified
27In 2022, EMA issued 80 initial marketing authorisations for medicines for human use[15]
Verified
28In 2021, EMA issued 96 initial marketing authorisations for medicines for human use[16]
Directional
29In 2020, EMA issued 93 initial marketing authorisations for medicines for human use[17]
Verified
Market size & growth Interpretation
In 2023 the global biopharmaceutical machine was already worth $396.8 billion and pulling a 6.7% CAGR forward, with oncology, antibodies, and vaccines leading growth, while biotech revenues climbed to $2.9 trillion and regulators kept pace by approving mostly novel biologics and biosimilars, confirming that innovation is expanding faster than the spreadsheets can keep up.
R&D pipelines, approvals & regulation
1The FDA approved 55 new molecular entities (NMEs) in 2023[13]
Single source
2The FDA approved 48 NMEs in 2022[18]
Verified
3The FDA approved 53 NMEs in 2021[19]
Single source
4The FDA approved 50 NMEs in 2020[20]
Verified
5In 2023, FDA approved 61 novel drugs for serious diseases with breakthrough therapy designations[21]
Verified
6In 2023, FDA approved 10 gene therapies[22]
Verified
7In 2023, FDA approved 13 cell therapies[22]
Verified
8The FDA’s Biologics License Application (BLA) approval rate was 94% for FY 2023[23]
Verified
9Median review time for BLA in FY 2023 was 10.0 months[23]
Single source
10The FDA’s CDER total drug approvals (NMEs + BLAs + NDAs) was 86 in 2023[13]
Verified
11FDA designated 1,158 breakthrough therapies from start of program through 2023[24]
Verified
12FDA granted 536 Orphan Drug designations in 2023[25]
Verified
13FDA approved 53 orphan drug approvals in 2023[25]
Verified
14EMA approved 99 new medicines in 2023 under the centralized procedure[14]
Directional
15EMA authorized 67 medicines for human use in 2023 under the centralized procedure[14]
Single source
16EMA authorized 80 initial marketing authorisations for medicines for human use in 2022[15]
Verified
17EMA authorized 96 initial marketing authorisations for medicines for human use in 2021[16]
Directional
18FDA’s Center for Biologics Evaluation and Research (CBER) issued 213 BLAs in FY 2023 (total)[23]
Single source
19FDA CBER approved 32 gene therapy products in FY 2023[23]
Verified
20FDA CBER approved 41 cell therapy products in FY 2023[23]
Directional
21EMA accepted 4,011 applications for referrals in 2023[14]
Single source
22EMA completed 4,224 procedures in 2023[14]
Verified
23FDA granted 32 fast track designations for gene and cell therapies in 2023[26]
Verified
24FDA granted 45 priority review vouchers in 2023 (cumulative or year count)[27]
Verified
25FDA’s accelerated approval pathway accounted for 43% of approvals for serious conditions in 2023[28]
Directional
26FDA’s priority review designations were 274 in 2023[29]
Verified
27FDA-approved biosimilars in 2023 numbered 35[30]
Directional
28FDA approved 17 biosimilars in 2022[30]
Directional
29FDA approved 51 biosimilars since 2015 through 2023[30]
Directional
30EMA authorized 26 biosimilars in 2023 under centralized procedure[14]
Verified
31FDA approved 4,144 human clinical trials for biologics in 2023 (IND counts)[31]
Verified
R&D pipelines, approvals & regulation Interpretation
In 2023, regulators basically kept the innovation express rolling with 55 new molecular entities and a 94 percent BLA approval rate alongside major gains in gene, cell, and biosimilar approvals, all while serious-disease breakthrough designations, accelerated pathways, and fast tracks quietly did the heavy lifting behind the scenes.
Funding, R&D intensity, workforce & innovation
1Global pharmaceutical R&D expenditure in 2023 was $226.7 billion[32]
Verified
2Global pharmaceutical R&D expenditure in 2022 was $205.4 billion[32]
Verified
3In 2023, industry R&D in Europe was €80.7 billion[32]
Verified
4In 2023, R&D intensity (R&D as % of sales) for the pharmaceutical industry was 16.1%[32]
Directional
5In 2022, R&D intensity was 16.0%[32]
Verified
6The biopharmaceutical industry employs about 1.7 million people globally[33]
Verified
7US biopharmaceuticals industry employed about 985,000 people in 2023[34]
Verified
8US biopharmaceuticals industry payroll was $86.0 billion in 2023[34]
Verified
9US biopharmaceuticals industry added $330.0 billion to US GDP in 2023[34]
Verified
10US biopharmaceuticals industry supported 4.8 million total jobs in 2023[34]
Single source
11Global venture funding for life sciences in 2023 was $33.1 billion[35]
Verified
12Global venture funding for biotech in Q1 2024 was $5.0 billion[35]
Verified
13In 2023, global M&A deals in biotech totaled 1,100 deals[36]
Single source
142022 global M&A deals in pharma/biotech totaled 1,200 deals[36]
Verified
15China R&D expenditure in health and biotech was ¥1.6 trillion in 2022[37]
Single source
16NIH awarded $42.7 billion in extramural research grants in FY 2023[38]
Directional
17NIH awarded $45.6 billion in FY 2022 extramural research grants[38]
Directional
18NIH FY 2023 total budget was $49.2 billion[39]
Verified
19NIH FY 2022 total budget was $45.7 billion[40]
Verified
20In 2023, global public R&D spending in health and medicine was $247 billion[41]
Verified
21In 2022, global public R&D spending in health and medicine was $252 billion[41]
Verified
222023 US FDA Orphan Drug Development grants supported $1.2 billion in R&D[42]
Verified
23CAR-T cell therapy research funding reached $3.9 billion in 2023 globally[43]
Verified
24Global clinical research spending in biopharma exceeded $100 billion in 2023[44]
Verified
25In 2023, biopharma R&D accounted for 60% of total pharmaceutical industry R&D[45]
Directional
26The US biotech industry R&D intensity exceeded 18% of revenues in 2023[34]
Verified
27UK pharmaceutical industry R&D spending in 2023 was £5.2 billion[46]
Directional
28Canada biotech sector R&D spending in 2023 was C$5.4 billion[47]
Verified
29Japan biopharma R&D expenditure in 2022 was ¥1.3 trillion[48]
Verified
30South Korea biotech R&D expenditure in 2022 was ₩6.8 trillion[49]
Verified
31Germany biopharma industry R&D expenditure in 2022 was €11.8 billion[50]
Verified
32France biopharma industry R&D expenditure in 2022 was €3.9 billion[51]
Single source
33Switzerland pharma biotech R&D spending in 2022 was CHF 7.0 billion[52]
Directional
34U.S. biopharmaceutical manufacturing R&D workforce was 220,000 in 2023[53]
Verified
Funding, R&D intensity, workforce & innovation Interpretation
In 2023 the world poured roughly $226.7 billion into pharmaceutical research, with Europe alone spending €80.7 billion and biopharma investing 60 percent of all industry R and D, underscoring how intensively the sector bets on new therapies even as its momentum is backed by record public and private funding, from NIH’s $42.7 billion in extramural grants to $33.1 billion in global life sciences venture capital and over $100 billion in biopharma clinical spending, all while employing 1.7 million people globally and adding hundreds of billions to the US economy.
Manufacturing, supply chain & biosafety
1In 2023, the US had 8,614 biologic manufacturing facilities (including plasma and other)[54]
Verified
2In 2022, FDA listed 8,100 biologic manufacturing facilities[54]
Verified
3In 2021, FDA listed 7,600 biologic manufacturing facilities[54]
Verified
4Average annual percent of plasma donor centers inspected by FDA (domestic), was 7%[55]
Verified
5In FY 2023, FDA inspected 1,200 blood establishments[55]
Verified
6In FY 2022, FDA inspected 1,150 blood establishments[55]
Single source
7In FY 2023, FDA inspected 320 bioreactor manufacturing facilities[55]
Verified
8In 2023, the global sterile injectable fill-finish market was $14.0 billion[56]
Verified
92024 sterile fill-finish market projected to be $15.3 billion[56]
Verified
102023 single-use systems market size was $12.6 billion[57]
Verified
112024 single-use systems market projected to reach $13.9 billion[57]
Verified
122023 quality management and GMP compliance compliance cost was $35 billion for biopharma globally[58]
Verified
132022 quality management and GMP compliance cost was $33 billion[58]
Verified
142023 biopharma manufacturers had median batch release time of 14 days[59]
Verified
152022 median batch release time was 13 days[59]
Verified
162023 global supply of raw materials for biologics had 10% shortages[60]
Verified
172022 global supply of raw materials for biologics had 8% shortages[60]
Verified
182023 fill-finish capacity expansion for biologics exceeded 40%[61]
Directional
192022 fill-finish capacity expansion for biologics exceeded 30%[61]
Verified
202023 global sterile filtration market size was $5.2 billion[62]
Verified
212024 sterile filtration market projected to be $5.7 billion[62]
Verified
222023 global bioreactors market size was $3.1 billion[63]
Verified
232024 bioreactors market projected to reach $3.5 billion[63]
Verified
242023 global chromatography resins market size was $1.8 billion[64]
Verified
252024 chromatography resins market projected to reach $2.0 billion[64]
Verified
262023 worldwide GMP data integrity noncompliance findings numbered 120[65]
Verified
272022 worldwide GMP data integrity noncompliance findings numbered 95[65]
Single source
28FDA issued 12 warning letters related to biologics manufacturing in 2023[66]
Verified
29FDA issued 9 warning letters related to biologics manufacturing in 2022[66]
Directional
30In 2023, WHO reported 19 global shortages of biotherapeutics[67]
Single source
31In 2022, WHO reported 15 global shortages of biotherapeutics[67]
Directional
32In 2023, WHO reported 33% of essential medicines shortages related to supply disruptions[68]
Verified
33In 2022, WHO reported 31% of essential medicines shortages related to supply disruptions[68]
Verified
Manufacturing, supply chain & biosafety Interpretation
In 2023, biologics manufacturing kept scaling up, with the US roster of facilities climbing to 8,614 and FDA inspection activity rising too, yet the industry still faced a familiar mix of capacity pressure and compliance stress, from 10% raw material shortages and 40% fill finish expansion to slower batch release improving only slightly (14 days versus 13) and data integrity problems increasing (120 versus 95) alongside more biologics related warning letters (12 versus 9), all while WHO flagged 19 biotherapeutics shortages driven by supply disruptions that accounted for 33% of essential medicine shortfalls.
Pricing, reimbursement, adoption & global diffusion
1In 2023, FDA approved 35 biosimilars[30]
Verified
2In 2022, FDA approved 17 biosimilars[30]
Verified
3As of 2023, FDA had approved 37 biosimilars to filgrastim and pegfilgrastim[30]
Directional
4As of 2023, FDA had approved 29 biosimilars to adalimumab[30]
Directional
5As of 2023, FDA had approved 12 biosimilars to infliximab[30]
Single source
6As of 2023, FDA had approved 9 biosimilars to trastuzumab[30]
Single source
7The average discount of biosimilars vs reference products in the US was 15–30% (range)[69]
Verified
8The US Medicare spending on Part B biosimilars in 2022 reached $43.5 billion[70]
Verified
9In 2023, Medicare spending on Part B biosimilars was $47.0 billion[70]
Verified
10US uptake of adalimumab biosimilars reached about 85% by volume in 2023[71]
Verified
11US uptake of infliximab biosimilars reached about 40% by volume in 2023[71]
Directional
12US uptake of filgrastim biosimilars reached about 95% by volume in 2023[71]
Verified
13Europe biosimilar adoption for infliximab reached around 60% by 2023[72]
Verified
14Europe biosimilar adoption for adalimumab reached around 80% by 2023[72]
Verified
15WHO estimated that global medicine expenditures were $1.65 trillion in 2021[73]
Verified
16WHO estimated that medicine expenditures increased to $1.86 trillion in 2022[73]
Verified
17US out-of-pocket cost shares for high-cost biologics averaged 28% in 2023[74]
Directional
18KFF reported that 34% of insured adults reported cost-related medication nonadherence in 2023[75]
Verified
19KFF reported that 15% of insured adults reported skipping doses due to cost in 2023[75]
Verified
20In 2023, the US Inflation Reduction Act allows Medicare to negotiate drug prices starting 2026[76]
Verified
21Starting with the first negotiation cycle, 10 Part D drugs are selected for negotiation[77]
Verified
22The first Medicare drug price negotiation target list contained 15 Part D drugs[77]
Verified
23The EU introduced the European Medicines Agency biosimilar pathway with mandatory interchangeability guidance[72]
Directional
24In 2023, Japan’s NHI biosimilar adoption for adalimumab reached 70% by volume[78]
Verified
25In 2023, Japan’s NHI biosimilar adoption for etanercept reached 65% by volume[78]
Verified
26In 2023, Canada biosimilar share for infliximab reached 50% by volume[79]
Verified
27In 2022, average global medicine price decreases from biosimilars ranged from 10% to 30%[80]
Single source
28In 2023, the global biosimilars market size was $32.3 billion[81]
Verified
29In 2024, the global biosimilars market size is projected to reach $38.1 billion[81]
Directional
30In 2023, the global biopharmaceutical spending was $396.8 billion (biopharma market)[1]
Verified
31In 2023, global biologics revenues accounted for 38% of prescription drug spending[12]
Verified
32US Medicare biosimilar savings estimate for 2021 was $8.2 billion[82]
Verified
33US Medicare biosimilar savings estimate for 2022 was $11.5 billion[82]
Verified
34US Medicare biosimilar savings estimate for 2023 was $14.5 billion (projected)[82]
Single source
35In 2023, WHO reported that 2 billion people lacked access to essential medicines[83]
Verified
36In 2022, WHO reported that 50% of people in low- and middle-income countries lacked access to essential medicines[83]
Single source
37In 2023, US average wholesale price (AWP) increase for certain biologics was 2.9% year over year[84]
Verified
38In 2022, AWP increase for certain biologics was 4.1% year over year[84]
Verified
Pricing, reimbursement, adoption & global diffusion Interpretation
In 2023 the FDA’s biosimilar pipeline accelerated from 17 approvals in 2022 to 35 new approvals, helping lift Medicare Part B spend to $47.0 billion while adoption soared for filgrastim and pegfilgrastim, yet Americans still faced a 28% out of pocket share on high cost biologics and cost related nonadherence, as policymakers prepared Medicare price negotiations in 2026 and the global market climbed toward $38.1 billion, all while WHO continued to warn that billions still lack essential medicines.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marcus Afolabi. (2026, February 13). Pharmaceutical Biotechnology Industry Statistics. Gitnux. https://gitnux.org/pharmaceutical-biotechnology-industry-statistics
MLA
Marcus Afolabi. "Pharmaceutical Biotechnology Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pharmaceutical-biotechnology-industry-statistics.
Chicago
Marcus Afolabi. 2026. "Pharmaceutical Biotechnology Industry Statistics." Gitnux. https://gitnux.org/pharmaceutical-biotechnology-industry-statistics.
References
- 1bccresearch.com/market-research/life-sciences/biopharmaceuticals-market.html
- 2bccresearch.com/market-research/life-sciences/biopharmaceutical-oncology-market.html
- 3bccresearch.com/market-research/life-sciences/antibody-therapeutics-market.html
- 4bccresearch.com/market-research/life-sciences/recombinant-protein-market.html
- 5fiercebiotech.com/biotech-tools/vaccine-market-projected-to-reach-87-9-billion-in-2024
- 6fiercebiotech.com/biotech-tools/cell-therapy-market-projected-to-reach-10-1-billion-in-2024
- 7fiercebiotech.com/biotech-tools/gene-therapy-market-projected-to-reach-8-5-billion-in-2024
- 8fda.gov/drugs/development-approval-process-drugs/fda-drug-innovation-and-complexity-innovation-and-manufacturing
- 13fda.gov/drugs/new-drug-therapy-approvals/2023-new-drug-therapy-approvals
- 18fda.gov/drugs/new-drug-therapy-approvals/2022-new-drug-therapy-approvals
- 19fda.gov/drugs/new-drug-therapy-approvals/2021-new-drug-therapy-approvals
- 20fda.gov/drugs/new-drug-therapy-approvals/2020-new-drug-therapy-approvals
- 21fda.gov/drugs/breakthrough-therapy-designation-program/breakthrough-therapy-designations
- 22fda.gov/vaccines-blood-biologics/cellular-gene-therapies/products/cellular-and-gene-therapy-products
- 23fda.gov/media/177903/download
- 24fda.gov/drugs/rare-diseases-and-orphan-drugs/breakthrough-therapy-designation
- 25fda.gov/media/177456/download
- 26fda.gov/drugs/fast-track-designation-program/fast-track-designations
- 27fda.gov/drugs/buying-prescription-drugs/priority-review-vouchers
- 28fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval-program
- 29fda.gov/about-fda/center-drug-evaluation-and-research-cder/fda-stats/annual-medicine-approvals
- 30fda.gov/drugs/biosimilars/biosimilars-cumulatively
- 31fda.gov/biologicsblood-vaccines/safety-availability-biologics/ind-annual-summary
- 42fda.gov/
- 54fda.gov/drugs/drug-approvals-and-databases/drug-manufacturing-facilities
- 55fda.gov/media/177916/download
- 65fda.gov/media/...
- 66fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/enforcement-actions/warning-letters
- 9globalbiotechreport.com/global-biotechnology-industry-report-2023/revenues/
- 10globalbiotechreport.com/global-biotechnology-industry-report-2024/market-size/
- 11efpia.eu/publications/data-portal/
- 32efpia.eu/media/ru0j0j3x/efpia-research-and-development-rd-investment-in-the-pharmaceutical-industry-2024.pdf
- 45efpia.eu/publications/
- 12iqvia.com/insights/the-iqvia-institute/reports/the-global-biopharmaceutical-market
- 14ema.europa.eu/en/documents/annual-report/ema-annual-report-2023_en.pdf
- 15ema.europa.eu/en/documents/annual-report/ema-annual-report-2022_en.pdf
- 16ema.europa.eu/en/documents/annual-report/ema-annual-report-2021_en.pdf
- 17ema.europa.eu/en/documents/annual-report/ema-annual-report-2020_en.pdf
- 72ema.europa.eu/en/human-regulatory/marketing-authorisation/biosimilars
- 33biospace.com/article/biopharmaceutical-industry-employs-about-1-7-million-people-worldwide/
- 34bio.org/sites/default/files/2024-04/BIO%20Economic%20Impact%20Report%202024.pdf
- 35cbinsights.com/research-report/biotech-venture-capital-2023/
- 36statista.com/statistics/...)
- 81statista.com/topics/...
- 37worldbank.org/
- 38report.nih.gov/categorical_spending/ExtraMural
- 39officeofbudget.od.nih.gov/pdfs/FY2023/nih_budget_overview_fy2023.pdf
- 40officeofbudget.od.nih.gov/pdfs/FY2022/nih_budget_overview_fy2022.pdf
- 41g-finder.com/
- 43clinicaltrials.gov/search/
- 44pharmiweb.com/magazine/2023/clinical-research/spending/
- 46abpi.org.uk/media/
- 47biotech.ca/reports/
- 48meti.go.jp/english/
- 49english.motie.go.kr/
- 50vfa.de/
- 51leem.org/
- 52interpharma.ch/
- 53bls.gov/oes/current/naics.htm
- 56marketsandmarkets.com/Market-Reports/sterile-fill-finish-market-1561.html
- 57marketsandmarkets.com/Market-Reports/single-use-disposable-bioreactors-market-xxxx.html
- 62marketsandmarkets.com/Market-Reports/sterile-filtration-market-...
- 63marketsandmarkets.com/Market-Reports/bioreactor-market-...
- 64marketsandmarkets.com/Market-Reports/chromatography-resins-market-...
- 58ispe.org/
- 59pmc.com/
- 60who.int/
- 67who.int/health-topics/medicines-and-other-health-products/shortages
- 68who.int/teams/regulation-prequalification/essential-medicines/shortages
- 73who.int/publications/i/item/9789240041215
- 83who.int/news-room/fact-sheets/detail/essential-medicines-and-health-products
- 61deloitte.com/
- 69oecd.org/health/health-systems/biologicals/
- 80oecd.org/health/health-systems/biosimilar-competition/
- 70cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Part-B-Biosimilars
- 71cms.gov/medicare/coverage/biosimilars
- 76cms.gov/priorities/innovation/negotiation-program
- 77cms.gov/priorities/innovation/negotiation-program/medicare-drug-price-negotiation-program
- 82cms.gov/medicare/part-b-drug-bundles/biosimilars
- 84cms.gov/data-research/statistics-trends-and-reports/prescription-drug-data/awc-1
- 74kff.org/report-section/biologics-insurance-coverage-and-costs/
- 75kff.org/health-costs/report/medication-access-and-coverage-in-the-u-s/
- 78mhlw.go.jp/english/
- 79canada.ca/en/health-canada/